Lifileucel, also known as AMTAGAVI, is an innovative cell therapy indicated for the treatment of melanoma. It involves the infusion of genetically modified T cells to target and eliminate cancer cells.

This therapy is designed to enhance the body's immune response against tumors, allowing for improved outcomes in patients with refractory or advanced disease.

Approval for Lifileucel was based on clinical trials demonstrating its effectiveness and safety profile.

Patients considering Lifileucel should consult with their healthcare provider to understand the risks and benefits associated with this treatment.

For more details